Q3 2024 EPS Estimates for Omnicell, Inc. Increased by Zacks Research (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research boosted their Q3 2024 earnings per share (EPS) estimates for shares of Omnicell in a research report issued on Tuesday, September 10th. Zacks Research analyst U. Biswas now forecasts that the company will post earnings per share of $0.17 for the quarter, up from their prior estimate of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q4 2024 earnings at $0.17 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.49 EPS.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. Omnicell’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.29 earnings per share.

Several other research firms also recently commented on OMCL. Bank of America upped their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. upped their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Wells Fargo & Company lifted their target price on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Benchmark restated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research note on Monday, July 15th. Finally, Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell has a consensus rating of “Moderate Buy” and a consensus target price of $37.83.

Omnicell Stock Down 0.6 %

Omnicell stock opened at $42.83 on Thursday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $56.06. The firm has a market capitalization of $1.97 billion, a PE ratio of -93.11, a P/E/G ratio of 50.19 and a beta of 0.83. The company’s 50-day moving average is $37.09 and its 200-day moving average is $31.52. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its stake in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the last quarter. EntryPoint Capital LLC raised its holdings in shares of Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares in the last quarter. CWM LLC raised its holdings in shares of Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares in the last quarter. Benjamin Edwards Inc. lifted its position in shares of Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Omnicell in the second quarter valued at about $104,000. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.